Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents

Pharmacokinetic characteristics of intravascular macromolecular magnetic resonance imaging (MRI) contrast agents with polyamidoamine dendrimer cores smaller than generation‐7 were previously studied in the literature. To evaluate the effects of greater hepatic uptake on the pharmacokinetics of the larger generation dendrimers, the MRI contrast agents GxD‐(1B4M‐Gd)  2 x+2 were synthesized with generation‐7, ‐8, and ‐9 polyamidoamine dendrimers and 2‐(p‐isothiocyanatobenzyl)‐6‐methyl‐diethylenetriaminepentaacetic acid (1B4M). Their pharmacokinetic characteristics in mice were compared with that of G6D‐(1B4M‐Gd)256. In biodistribution and dynamic micro‐MRI studies, significantly less renal accumulation of G7D‐(1B4M‐Gd)512, G8D‐(1B4M‐Gd)1024, and G9D‐(1B4M‐Gd)2048 was shown compared to G6D‐(1B4M‐Gd)256 (P < 0.01). There was a significantly greater accumulation of G8D‐(1B4M‐Gd)1024 and G9D‐(1B4M‐Gd)2048 in the liver compared to G6D‐(1B4M‐Gd)256 and G7D‐(1B4M‐Gd)512 (P < 0.01). The highest blood retention of all dendrimer‐based MRI contrast agents was exhibited by G7D‐(1B4M‐Gd)512 (P < 0.01). The normal and intratumoral fine vessels of approximately 100 μm diameter were visualized in normal or tumor‐bearing mice by high resolution three‐dimensional‐micro‐MR angiographs with G7D‐(1B4M‐Gd)512 and G8D‐(1B4M‐Gd)1024 with good vessel‐to‐soft tissue contrast. In summary, increased accumulation in the liver with concomitant decreased uptake in the kidney was caused by increased molecular sizes of the dendrimer‐based MRI contrast agents. J. Magn. Reson. Imaging 2001;14:705–713. © 2001 Wiley‐Liss, Inc.

[1]  M. Brechbiel,et al.  Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.

[2]  M. Brechbiel,et al.  3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent , 2001, Magnetic resonance in medicine.

[3]  M. Brechbiel,et al.  Novel intravascular macromolecular MRI contrast agent with generation‐4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine , 2001, Magnetic resonance in medicine.

[4]  M. Brechbiel,et al.  3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties , 2001, Magnetic resonance in medicine.

[5]  M. Brechbiel,et al.  Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. , 2001, Bioconjugate chemistry.

[6]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[7]  J A Frank,et al.  Synthesis and relaxometry of high‐generation (G = 5, 7, 9, and 10) PAMAM dendrimer‐DOTA‐gadolinium chelates , 1999, Journal of magnetic resonance imaging : JMRI.

[8]  M. Brechbiel,et al.  Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. , 1999, Bioconjugate chemistry.

[9]  N. Hylton,et al.  Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body , 1996, Journal of magnetic resonance imaging : JMRI.

[10]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[11]  P. Singh,et al.  Starburst dendrimers: enhanced performance and flexibility for immunoassays. , 1994, Clinical chemistry.

[12]  R. Brasch,et al.  Effect of varying the molecular weight of the MR contrast agent Gd‐DTPA‐polylysine on blood pharmacokinetics and enhancement patterns , 1994, Journal of magnetic resonance imaging : JMRI.

[13]  J. Fréchet,et al.  Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. , 1994, Science.

[14]  Martin W. Brechbiel,et al.  Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging , 1994 .

[15]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[16]  R. Barth,et al.  Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. , 1994, Bioconjugate chemistry.

[17]  R Weissleder,et al.  A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. , 1993, Radiology.

[18]  A Hemmingsson,et al.  Mr Imaging of Acute Myocardial Infarction in Pigs Using GD-Dtpa-Labeled Dextran , 1992, Acta radiologica.

[19]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[20]  M. Moseley,et al.  Magnetic Resonance Imaging Detection of an Experimental Pulmonary Perfusion Deficit Using a Macromolecular Contrast Agent: Polylysine–Gadolinium-DTPA40 , 1992, Investigative radiology.

[21]  K. C. Li,et al.  In vivo MR evaluation of Gd-DTPA conjugated to dextran in normal rabbits. , 1992, Magnetic resonance imaging.

[22]  M. Moseley,et al.  Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues. , 1990, Radiology.

[23]  William A. Goddard,et al.  Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .

[24]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.

[25]  M. Ogan,et al.  Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. , 1987, Investigative radiology.

[26]  K. Hubner,et al.  Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. , 1987, Radiology.

[27]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[28]  J. Toguchida,et al.  Recognition of serum alkaline phosphatase by murine monoclonal antibodies against human osteosarcoma cells. , 1986, Cancer research.